1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al.. "Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan" , China JAMA. 2020; 323(11):1061–9. doi: DOI: 10.1001/jama.2020.1585

2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, "China Medical Treatment Expert Group for Covid-19" . New England journal of medicine2020; 382(18): 1708–20. DOI: 10.1056/NEJMoa2002032

3. Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al.. "Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019" . J Intern Med. 2020; 288(3):335–44. doi: DOI: 10.1111/joim.13089

4. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al.. "Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan" , China. Allergy. 2020; 75(7):1730–41. doi: DOI: 10.1111/all.14238.

5. "Worldometer: Coronavirus" ( https://www.worldometers.info/coronavirus/)

6. "COVID-19 Bilgilendirme Platformu" ( https://covid19.saglik.gov.tr).

7. Velavan TP, Meyer CG. "The COVID-19 epidemic" . Trop Med Int Health.2020; 25(3):278–80. doi: DOI: 10.1111/tmi.13383

8. Conti P, Caraffa A, Gallenga CE, Kritas SK, Frydas I, Younes A, et al.. "The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem" . J Biol Regul Homeost Agents. 2021; 35(1):1–4. doi: DOI: 10.23812/21-3-E. PMID: 33377359.

9. Naqvi AAT, Fatima K, Mohammad T, Fatima U, Singh I.K, Singh A, et al.. "Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach" . Biochim. Biophys. Acta Mol. Basis Dis. 2020; 1866(10):165878. doi: DOI: 10.1016/j.bbadis.2020.165878. PMID: 32544429; PMID: PMC7293463

10. Mishra SK, Tripathi T. "One year update on the COVID-19 pandemic: Where are we now?" . Acta Trop. 2021Feb; 214:105778. doi: DOI: 10.1016/j.actatropica.2020.105778. PMID: 33253656; PMID: PMC7695590.

11. Wang R, Hozumi Y, Yin C, Wei GW. "Mutations on COVID-19 diagnostic targets" . Genomics.2020; 112(6):5204–13. doi: DOI: 10.1016/j.ygeno.2020.09.028

12. Washington NL, Gangavarapu K, Zeller M, Bolze A, Cirulli ETBarrett KMS, et al.. "Emergence and rapid transmission of SARSCoV-2 B.1.1.7 in the United States" . Cell. 2021; 184(10):2587–94.e.13. doi: DOI: 10.1016/j.cell.2021.03.052.

13. Aleem A, Akbar Samad AB, Slenker AK. "Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). 2021 Apr 11" . In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021Jan–. PMID: 34033342.

14. Davies NG, Barnard RC, Jarvis CI, Kucharski AJ, Munday J, Pearson CAB, et al.. "Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England" . MedRxiv.2020.12.24. 20248822. doi: DOI: 10.1101/2020.12.24.20248822

15. Gupta R, Misra A. "Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc)" . Diabetes Metab Syndr.2020; 14(3):251–4. doi: DOI: 10.1016/j.dsx.2020.03.012.

16. Villoutreix BO, Calvez V, Marcelin AG, Khatib AM. "In Silico Investigation of the New UK (B.1.1.7) and South African (501Y. V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface" . Int J Mol Sci.2021; 22(4):1695. doi: DOI: 10.3390/ijms22041695. PMID: 33567580; PMID: PMC7915722.

17. Eaaswarkhanth M, Al Madhoun A, Al-Mulla F. "Could the D614G substitution in the SARS-CoV-2 spike (S) protein be associated with higher COVID-19 mortality?" . Int J Infect Dis. 2020; 96:459–60. doi: DOI: 10.1016/j.ijid.2020.05.071

18. Grabowski F, Preibisch G, Giziński S, Kochańczyk M, Lipniacki T. "SARS-CoV-2 Variant of Concern 202012/01 Has about Twofold Replicative Advantage and Acquires Concerning Mutations" . Viruses.2021; 13(3):392. doi: DOI: 10.3390/v13030392. PMID: 33804556; PMID: PMC8000749.

19. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al.. "Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus" . Cell. 2020; 182:812–27e819. doi: DOI: 10.1016/j.cell.2020.06.043.

20. Davies NG, Jarvis CI, CMMID COVID-19 Working Group, Jewell NP, Diaz-Ordaz K, Keogh RH, et al.. "Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01" . Preprint. medRxiv. 2021;2021.02.01.21250959. doi: DOI: 10.1101/2021.02.01.21250959

21. Lorenzo-Redondo R, Nam HH, Roberts SC, Simons LM, Jennings LJ, Qi C, et al.. "A clade of SARS-CoV-2 viruses associated with lower viral loads in patient upper airways" . EBioMedicine. 2020Dec; 62:103112. doi: DOI: 10.1016/j.ebiom.2020.103112. PMID: 33186810; PMID: PMC7655495.

22. Groves DC, Rowland-Jones SL, Angyal A. "The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design" . Biochem Biophys Res Commun. 2021; 538:104–7. doi: DOI: 10.1016/j.bbrc.2020.10.109

23. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al.. "Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England" . Nature. 2021; 593(7858):266–9. doi: DOI: 10.1038/s41586-021-03470-x

24. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al.. "The impact of COPD and smoking history on the severity of Covid-19: a systemic review and meta-analysis" . J Med Virol. 2020Oct; 92(10):1915–21. doi: DOI: 10.1002/jmv.25889

25. Kant A, Comoglu S, Ozturk S, Aydin E, Yilmaz G. "Does Chronıc Obstructıve Lung Dısease Affect The Severıty Of Covıd-19 Infectıon?" . Kırıkkale University Faculty Of Medicine Journal, 2020: 22 (3), 440–4. doi: DOI: 10.24938/Kutfd.810344

26. Uddin M, Mustafa F, Rizvi TA, Loney T, Al Suwaidi H, Al-Marzouqi AHH, et al.. "SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions" . Viruses. 2020; 12(5):526. doi: DOI: 10.3390/v12050526. PMID: 32397688; PMID: PMC7290442.

27. Conti P, Caraffa A, Gallenga CE, Kritas SK, Frydas I, Younes A, et al.. "The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem" . J Biol Regul Homeost Agents. 2021; 35(1):1–4. doi: DOI: 10.23812/21-3-E. PMID: 33377359.

28. Yadav T, Srivastava N, Mishra G, Dhama K, Kumar S, Puri B, et al.. "Recombinant vaccines for COVID-19" . Hum Vaccin Immunother. 2020; 16(12):2905–12. doi: DOI: 10.1080/21645515.2020.1820808

29. Knoll MD, Wonodi C. "Oxford-AstraZeneca COVID-19 vaccine efficacy" . Lancet.2021; 397(10269):72–4. doi: DOI: 10.1016/S0140-6736(20)32623-4

30. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. "What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2" . Lancet Infect Dis.2021; 21(2):e26–e35. doi: DOI: 10.1016/S1473-3099(20)30773-8. PMID: 33125914; PMID: PMC7837315.